Health-related quality of life in elderly, newly diagnosed multiple myeloma patients treated with VMP versus MP: Results from the VISTA trial
European Journal of Haematology,  Clinical Article

Delforge M et al. – The findings demonstrate clinically meaningful, transitory Health–related quality of life (HRQoL) decrements with bortezomib–melphalan–prednisone (VMP) and relatively lower HRQoL versus melphalan–prednisone (MP) during early treatment cycles, associated with the expected additional toxicities. However, HRQoL is not compromised in the long–term, recovering by the end–of–treatment visit to be comparable versus MP.

Please login or register to follow this author.
► Click here to access PubMed, Publisher and related articles...
<< Previous Article | Next Article >>

    Currently, there are no available articles.

Your Unread Messages in Physician Assistant

See All >> Messages include industry-sponsored communications and special communications from MDLinx

Most Popular Physician Assistant Articles

Indexed Journals in Physician Assistant: Advance for Physicians Assistants, American Family Physicianmore